How your patients with HF and iron deficiency may benefit from an IV iron treatment:
- May reverse iron deficiency induced cardiac remodeling and improve left ventricular ejection fraction (LVEF).3
- Even in healthy patients, less than 10% of oral iron is absorbed.5* With IV iron, 100% of iron is delivered into the bloodstream.
- IV iron therapy may help improve QoL.6,7
*A typical dose is a 300-mg ferrous sulfate tablet or 320-mg ferrous gluconate tablets (taken 3 to 4 times daily). Approximately 10% of oral iron is absorbed.5
Discover a treatment option
- An IV iron is available for certain patients with HF and iron deficiency.
Identify and treat iron deficiency before it worsens to anemia
- The clinical benefits of treating iron deficiency outweigh the additional damage that may be done from waiting for it to worsen to IDA8
- Reduced oxygen delivery to metabolizing tissues in anemic patients may trigger a host of hemodynamic alterations including low arterial blood pressure which may worsen HF in some patients8
- In patients with HF, anemia may double the risk of death and when adjusted, may increase the risk of death by 1.5 fold when paired with chronic kidney disease (CKD)8
References: 1. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):e263-e421. doi.org/10.1016/j.jacc.2021.12.012 2. von Haehling S, Ebner N, Evertz R, et al. Iron deficiency in heart failure: An overview. JACC Heart Fail. 2019;7(1):36-46. doi:10.1016/j.jchf.2018.07.015 3. López-Vilella R, Lozano-Edo S, Arenas Martin P, et al. Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction. ESC Heart Fail. 2022;9(1):133-145. doi:10.1002/ehf2.13753 4. Lewis GD, Molhotra R, Hernandez AF, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency the IRONOUT HF randomized clinical trial. JAMA. 2017;317(19):1958-1966. doi:10.1001/jama.2017.5427 5. Zhu A, Kaneshiro M, Kaunitz JD. Evaluation and treatment of iron deficiency anemia: a gastroenterological perspective. Dig Dis Sci. 2010;55(3):548-559. doi:10.1007/s10620-009-1108-6 6. Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575-582.e3. doi:10.1016/j.ahj.2013.01.017 7. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657-668. doi:10.1093/eurheartj/ehu385 8. Anand IS, Gupta P. Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation. 2018;138(1):80-98. doi:10.1161/CIRCULATIONAHA.118.030099 9. Beverina I, Razionale G, Ranzini M, et al. Early intravenous iron administration in the emergency department reduces red blood cell unit transfusion, hospitalisation, re-transfusion, length of stay and costs. Blood Transfus. 2020;18(2):106-116. doi:10.2450/2019.0248-19 10. LaVallee C, Bansal I, Kamdar S, et al. Relationship between initial parenteral iron therapy dosing and treatment effectiveness: a real-world retrospective analysis. J Blood Med. 2022;13:133-142. doi:10.2147/JBM.S349070